Harald Baumeister
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (10)
The college years can be accompanied by mental distress. Internet- and mobile-based interventions (IMIs) have the potential to improve mental health but adherence is problematic. Psychological guidance might promote adherence but is resource intensive. In this three-armed randomized controlled trial, “guidance on demand” (GoD) and unguided (UG) adherence-promoting versions of the seven-module IMI StudiCare Mindfulness were compared with a waitlist control group and each other. The GoD participants could ask for guidance as needed. A total of 387 students with moderate/low mindfulness were recruited. Follow-up assessments took place after 1 (t1), 2 (t2), and 6 (t3) months. Post-intervention (t2), both versions significantly improved the primary outcome of mindfulness (d = 0.91–1.06, 95% CI 0.66–1.32) and most other mental health outcomes (d = 0.25–0.69, 95% CI 0.00–0.94) compared with WL, with effects generally persisting after 6 months. Exploratory comparisons between UG and GoD were mostly non-significant. Adherence was low but significantly higher in GoD (39%) vs. UG (28%) at the 6-month follow-up. Across versions, 15% of participants experienced negative effects, which were mostly mild. Both versions effectively promoted mental health in college students. Overall, GoD was not associated with substantial gains in effectiveness or adherence compared with UG. Future studies should investigate persuasive design to improve adherence.
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Objective Partners of cancer patients are the primary supporters and burdened at the same time. Support for partners is hitherto scarce and existing offers are rarely used. The PartnerCARE online intervention was specifically developed to address the caregiving partners' needs. This two‐arm parallel randomized controlled trial (RCT) evaluates the feasibility, acceptability, and potential efficacy of PartnerCARE. Methods Sixty German‐speaking partners of patients with various cancer entities were randomized into two conditions: intervention group (IG) with PartnerCARE ( N = 30) or waitlist‐control group ( N = 30). Participants completed online questionnaires at baseline (T0), post‐treatment (T1) and 4‐months follow‐up (T2). Feasibility and acceptability outcomes included dropout rates, use and acceptance of PartnerCARE, individual user/e‐coach feedback as well as negative effects. Relevant efficacy outcomes were assessed to test for potential intervention effects. Results Recruitment success illustrates demand for and acceptability of PartnerCARE. Satisfaction with the intervention was high (Client Satisfaction Questionnaire adapted to Internet‐based interventions, T1: M = 24.66, SD = 6.42) and 73.3% of participants completed the intervention. Study dropout rate was low (T1: 17%, T2: 29%). More positive than negative side effects of the intervention were identified, and negative ones were mainly related to ”intrapersonal change”. For efficacy outcomes we found effects over time, with strongest effects within the IG from T0 to T1 in psychological distress ( d = 0.73, 95%‐CI: [0.34; 1.12]) and anxiety (0.66, [0.26; 1.04]), but no group effects were significant at T1 and T2. Conclusions PartnerCARE is feasible, acceptable and potentially efficacious. Based on received feedback, PartnerCARE is currently undergoing further development and subsequently efficacy will be investigated in a RCT. Trial Registration : German Clinical Trial Registration: DRKS00017019. Registered on 08 April 2019.
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Collaborators (6)
Dirk Lehr
Professor
Leuphana University of Lüneburg
Yannik Terhorst
Ulm University
Klaus Hönig
-
Janika Thielecke
Vrije Universiteit Amsterdam
Martin Weiß
University Hospital Würzburg
Lasse B. Sander
University of Freiburg
Make your next move.
Prepare your application
Review drafts before you send them.